Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioharvest Sciences Inc CNVCF


Primary Symbol: C.BHSC

BioHarvest Sciences Inc. is a Canada-based biotechnology company. The Company offers Botanical Synthesis, its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. The Company is leveraging its Botanical Synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. The Company operates through two segments: Nutraceuticals and Pharmaceuticals. The Company offers a polyphenol/antioxidant superfruit product called VINIA, which is a red grape powder that supplies the benefits of red wine consumption but without the sugar, calories and alcohol found in wine.


CSE:BHSC - Post by User

Post by lscfaon Aug 23, 2021 1:05pm
179 Views
Post# 33748883

Cronos Group and Ginkgo Bioworks Announce Milestone

Cronos Group and Ginkgo Bioworks Announce Milestone

By achieving commercial scale production of CBG, the companies are on track to enable access to rare cannabis molecules

 

https://www.globenewswire.com/news-release/2021/08/23/2284750/0/en/Cronos-Group-and-Ginkgo-Bioworks-Announce-Achievement-of-Equity-Milestone-in-Partnership-to-Produce-Cultured-Cannabinoids.html

 

<< Previous
Bullboard Posts
Next >>